Dogwood Therapeutics Inc (DWTX)
Dogwood Therapeutics, Inc. is a development-stage biotechnology company focused on therapies for pain and fatigue-related disorders. The company’s pipeline includes IMC-1, a combination of famciclovir and celecoxib that has completed a Phase 2b clinical trial for fibromyalgia; Halneuron, which is being studied in Phase 2b trials for chemotherapy-induced neuropathic pain and cancer pain and is also in preclinical development for acute surgical pain; IMC-2, a combination of valacyclovir and celecoxib designed to suppress herpesvirus activation; and Serpin Peptide 16, which is in early Phase 1 development for neuropathy associated with neurotoxic chemotherapeutic agents. Formerly known as Virios Therapeutics, Inc., the company adopted its current name in October 2024. Dogwood Therapeutics was founded in 2012 and is based in Alpharetta, Georgia.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-DWTX
|
$2.18
|
44.5% Upside
|
Undervalued
|
$14
|
827.2% Upside
|
Bargain
|
Fair
|
0.0%
|
November 5, 2026
|
0.8x
|
51.329 M
|
44.905 M
|
0.2%
|
17.1%
|
-1.1
|
41.9%
|
